Adrian's practice is principally directed towards patent prosecution, licensing and related litigation, primarily in the pharmaceutical and biotechnology sectors.

Adrian Zahl is a partner of Ridout & Maybee LLP in the firm's Ottawa office. His practice is principally directed towards patent prosecution, licensing and related litigation, primarily in the pharmaceutical and biotechnology sectors. 

Adrian also has expertise in copyright, author/publisher agreements and research contracts.

Prior to entering law, Adrian worked on projects that related to cell biology and neurochemical pathways in research labs at MIT and McGill University. Adrian regularly speaks at conferences on a variety of intellectual property topics, including pharmaceuticals and licensing.

B.Sc. (Biology), University Scholar, 1981, McGill University
LL.B., 1985, McGill University
Barrister & Solicitor, Province of Ontario, 1987
Registered Trade-mark Agent, Canada, 1987
Registered Patent Agent, Canada, 1991

Intellectual Property Institute of Canada (IPIC), Associate
Canadian Bar Association (CBA)
Association of University Technology Managers (AUTM)
Member of Editorial Board of CLB's Canadian Patent Reporter (CPR)

“International News – Canadian Update” Association of University of Technology Managers bi-monthly newsletter (ongoing)

David Heller and Adrian Zahl, “Proposed regulations to adjust generic balance,” Managing Intellectual Property (Focus- Life Science: Canada), March 2005

“Pharmaceuticals and the law: as patent laws converge, attention shifts to ‘data protection’” The Metropolitan Corporate Counsel, Vol 13 no. 2, February 2005, pg. 24

“Patenting of Higher Life Forms in Canada”, Biotechnology Law Report Vol. 23, pg. 556-560 October 2004

Editor, “International Pharmaceutical Law and Practice”, Matthew Bender/Lexis Nexis New York (October 2004)